Pharma
-
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
By Meagan Parrish • Aug. 8, 2025 -
Q&A
Inside AstraZeneca’s long-game strategy in lung cancer
New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.
By Michael Gibney • Aug. 7, 2025 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineRare diseases
As drug developers find promise in the rare diseases, deals and treatments are on the rise
By PharmaVoice staff -
PBM reform was dropped from Trump’s spending bill. It could have saved billions.
The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.
By Alexandra Pecci • Aug. 6, 2025 -
David Altshuler, geneticist who helped transform Vertex, to retire next year
Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”
By Ben Fidler • Aug. 5, 2025 -
Let’s make a deal? Big Pharma execs express varying views on their M&A future
Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.
By Michael Gibney • Aug. 5, 2025 -
Drugmakers score policy win in a prolonged fight against 340B
A new pilot program from HHS would alter the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.
By Amy Baxter • Aug. 4, 2025 -
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.
By Michael Gibney • Aug. 1, 2025 -
C-suite shuffles ripple through pharma
Novo Nordisk, Kenvue and Jazz Pharmaceuticals announced changes at the top this month.
By Meagan Parrish • July 31, 2025 -
Retrieved from Vinay Prasad on May 08, 2025
Dr. Vinay Prasad, controversial FDA official, abruptly departs agency
Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.
By Ben Fidler • July 30, 2025 -
Roche pushes ahead with late-comer strategy in obesity
The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.
By Amy Baxter • July 30, 2025 -
Could bispecifics unseat Keytruda from its oncology throne?
Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.
By Kelly Bilodeau • July 28, 2025 -
From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity
The studies are contributing preclinical advances for some of the world’s biggest blockbusters.
By Michael Gibney • July 25, 2025 -
Pharma’s turbo spending spree on US manufacturing
The industry’s push to expand American drug production isn’t abating as threats of tariffs loom.
By Meagan Parrish • July 24, 2025 -
How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.
By Alexandra Pecci • July 24, 2025 -
Who is Dr. George Tidmarsh, the new director of CDER?
Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.
By Meagan Parrish and Michael Gibney • July 23, 2025 -
Novartis’ Zolgensma sales fall again as gene therapy market woes persist
Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?
By Michael Gibney • July 22, 2025 -
3 major patent losses this year — and a key strategy to fill the gaps
Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.
By Kelly Bilodeau • July 21, 2025 -
Why FDA’s CRL release could open the door to lawsuits against pharma
In a push for “radical transparency” the FDA released 200 CRLs for drugs that were later approved — some of which are now public for the first time.
By Meagan Parrish • July 18, 2025 -
J&J accelerates past Stelara’s fall with better-than-expected portfolio growth
Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.
By Michael Gibney • July 17, 2025 -
FDA invites more data from abroad — with a wary eye on China
The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.
By Amy Baxter • July 16, 2025 -
Q&A
Need a DTC platform? Here’s how one company built its own.
Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med.
By Amy Baxter • July 14, 2025 -
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.
By Jonathan Gardner • July 11, 2025 -
Pricing watchdog will take on the rising cost of drugs at launch
ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from a patient perspective.
By Michael Gibney • July 10, 2025 -
Trump says ‘very high’ pharmaceutical tariffs coming soon
While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.
By Philip Neuffer • July 9, 2025 -
First 90 Days
As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
Simone Steiner recently joined the French company to set the stage for launch.
By Amy Baxter • July 9, 2025